Extrait

To demonstrate that the immunogenicity of GSK Biologicals’ DTPa-IPV/Hib vaccine administered at 2, 3 and 4 months of age (Group A) is non-inferior to that of the concomitant administration of GSK Biologicals’ DTPa/Hib and IPV vaccines at the same age (Control Group), in terms of immune response to all vaccine antigens, one month after the third vaccine dose.

Critère d'inclusion

• Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases

Liens

• euctr